
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||
Perspective |
Author's Affiliation: Department of Leukemia and Epigenetics Center, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
Requests for reprints: Jean-Pierre Issa, Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 428, Houston, TX, 77030. Phone: 713-745-2260; Fax: 713-796-0318; E-mail: jpissa{at}mdanderson.org.
Abstract
The fields both of cancer prevention and epigenetics have matured to a point where their intersection deserves sustained attention. There now is strong evidence for an epigenetic component of early neoplasia, and data on the cancer preventive properties of epigenetic modulation are emerging. With preclinical proof of principle at hand, the challenge is to translate these epigenetic findings into testable clinical hypotheses.
Key Article
Cancer Prevention Research 2008 0: 1940-6207.CAPR-07-0008v1.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |